We then examined the associations of CRC with variants in the genes encoding 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), Niemann-Pick C1-Like 1 (NPC1L1), and proprotein convertase subtilisin/kexin type 9 (PCSK9), which are the targets of three commonly used LDL-lowering drugs (statins, ezetimibe, and PCSK9 inhibitors, respectively). This evidence concerns the gene NPC1L1 and colorectal carcinoma.